INDUSTRY WATCH
HealthEdge and Zelis announce strategic partnership to streamline healthcare payments
HealthEdge and Zelis have announced a strategic partnership aimed at modernizing the healthcare payment landscape .
The collaboration will leverage HealthEdge ’ s next generation core administrative processing system ( CAPS ) and the Zelis Advanced Payments Platform ( ZAPP ) to enhance the efficiency , accuracy and transparency of healthcare payments .
“ Health Plans have many challenges , including expanding to new markets , adopting valuebased care payment arrangements , meeting evolving industry regulations and more ,” says Alan Stein , Chief Product and Strategy Officer , HealthEdge .
“ Plans must maximize member cost savings and streamline the payment process to make it more efficient .”
Building upon an existing adjudication integration partnership , the collaboration aims to reduce friction and enhance the member and provider experience .
he integration of HealthEdge ’ s modern cloud-based platform with Zelis ’ single-hub payments and data solution streamlines workflows , minimizes custom code and supports a seamless payment process .
This ensures seamless payment interactions between health plans , providers and members , improving
satisfaction and reducing friction .
“ ZAPP is the industry ’ s first integrated payments and communications platform delivering digital conveniences and experiences that benefit payers , providers and members ,” says Yusuf Qasim , President , Payments Optimization , Zelis .
“ In partnership with HealthEdge , we can help resource-constrained health plans modernize their payments experience and seamlessly scale into new markets and reach providers and members without further implementation .”
With the integration of HealthEdge and Zelis systems , health plans will benefit from more efficient and less complex data exchange , reducing administrative burden .
The out-of-the-box integration – enabled by advanced technologies and industry expertise – paves the way for an automated payment process that can deliver more value to health plans , providers and members .
Additional key investigators include Wyss Institute Director of Translational R & D Kenneth Carlson , Ph . D ., a drug discovery and development specialist with extensive industry experience and Wyss Institute Core Faculty member William Shih , Ph . D ., who developed a DNA origami platform that allows the precise and highly effective presentation of RNA drugs , cancer and pathogen-derived antigens and immune activating adjuvants to the immune system .
Shih ’ s team will provide their DNA nanotechnology approach as an additional drug delivery option .
The collaboration is another validation of the potential for enzymatic synthesis to address the needs of a rapidly expanding RNA therapeutic market as the industry faces demand for RNA production that cannot be met by chemical synthesis alone . It builds upon recent important progress shared by EnPlusOne , including the breakthrough synthesis of the antisense strand of the commercially approved siRNA drug , Leqvio ( inclisiran ), a treatment for hypercholesteremia ( high cholesterol ) licensed from Alnylam Pharmaceuticals , Inc . by Novartis , that currently addresses a multi-million patient population .
EnPlusOne was launched by the Wyss Institute in 2022 to commercialize its enzymatic RNA oligonucleotide synthesis technology developed in the laboratory of co-founder George Church , PhD .
Seed financing was led by Northpond Ventures , with participation from Breakout Ventures , Coatue and individual investors . p
74 INTELLIGENTCIO NORTH AMERICA www . intelligentcio . com